resorption and differentiation of PBMCs, suggesting these inhibitors for future treatment of inflammatory bone loss such as periodontitis.
K E Y W O R D S
aminothiazoles, bone resorption, human PBMCs, lipopolysaccharide, microsomal prostaglandin E synthase-1, osteoclastogenesis, osteoclasts, periodontal ligament cells, prostaglandin E 2 , RAW 264.7 cells
| INTRODUCTION
In chronic inflammatory conditions including periodontitis and rheumatoid arthritis, bone loss is initiated by unresolved inflammation in the neighbouring tissues leading to pathological osteoclastogenesis. 1 During osteoclastogenesis, osteoclast progenitors, recruited from the monocytic linage, differentiate into pre-osteoclasts, fuse
and form large multinucleated cells and finally mature into activated osteoclasts that start to express tartrate-resistant acid phosphatase (TRAP) and release acid and collagen-degrading enzymes resulting in bone resorption. 1, 2 Osteoclastogenesis is regulated by a broad range of molecules and stimuli, including cytokines, prostaglandins and growth factors, which directly/indirectly regulate the production of osteoclastogenic molecules by various cell types, including stromal cells, osteoblast, osteocytes or resident fibroblasts. 1 The main signalling molecules regulating osteoclast formation are macrophage colony stimulating factor (M-CSF), receptor activator of nuclear factor κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG). RANKL and OPG are mainly produced by osteoblasts, osteocytes, resident cells such as periodontal ligament (PDL) cells, and in case of inflammation also by activated T-cells. 1 Whereas OPG is the main osteoclastogenesis-inhibitory molecule, specifically increasing bone density, RANK-RANKL and M-CSF are main molecules inducing bone resorption. 1, 3 The latter can also be induced through periodontal bacteria or bacterial components such as lipopolysaccharide (LPS) acting via Toll-like receptors (TLRs) 4 and 2, leading to increased expression of RANKL and other proinflammatory cytokines and osteoclastogenesis-stimulating molecules, including TNFα, interleukin (IL)-1 and M-CSF. 1, 3 In vitro experiments have reported that PDL cells, mainly producing OPG, adapt to bacterial stimuli by producing increased levels of osteoclastogenesis-stimulating molecules, thus increasing bone resorption. 3 The inflammatory mediator prostaglandin E 2 (PGE 2 ) may affect inflammation-induced osteoclastogenesis by stimulation of osteoblasts/stromal cells or by direct stimulation of osteoclast progenitor cells. 4 PGE 2 is synthesised sequentially by the enzymes phospholipase A 2 , cyclooxygenases (COX-1 and COX-2) and the final prostaglandin E synthases (PGES). 4 Three isoforms of PGES have been identified; the inducible microsomal PGES-1 (mPGES-1), and the constitutively expressed membrane-associated PGES-2 and cytosolic PGES. [5] [6] [7] [8] [9] In the chronic inflammatory disease periodontitis, elevated levels of PGE 2 have been reported in gingival crevicular fluid of patients with periodontitis suggesting this mediator as a predictor of alveolar bone loss. 10, 11 Increased levels of PGE 2 correlate well with enhanced levels of COX-2 and mPGES-1, expressed also in inflamed gingival tissues. 9, 11 Controlling the production of PGE 2 through COX-inhibition, using non-steroidal anti-inflammatory drugs (NSAIDs) or selective COX-2 inhibitors, have been reported to decrease the progression of alveolar bone loss and gingival inflammation in periodontitis. [11] [12] [13] [14] However, long-term treatment with NSAIDs and selective COX-2 inhibitors is associated with adverse side effects such as gastrointestinal toxicity and increased the risk of druginduced heart failure. [15] [16] [17] [18] [19] [20] The downstream enzyme mPGES-1, responsible for PGE 2 production, is therefore an attractive target for new anti-inflammatory drugs with potentially fewer side effects compared to COX-inhibitors. 21 However, to the best of our knowledge, mPGES-1 inhibitors are not yet available for clinical use.
The aminothiazoles TH-848 and TH-644 have been identified as mPGES-1 inhibitors by docking models towards the three-dimensional crystal structure of mPGES-1. 22 These compounds inhibit cytokine-induced PGE 2 synthesis in gingival fibroblasts and in vitro enzyme activity of mPGES-1 as well as reduce alveolar bone resorption in vivo. 22 In addition, the aminothiazoles inhibited both RANKLand LPS-stimulated osteoclast formation of the osteoclast progenitor cell line RAW 264.7. 23 In the present study, we aimed to further elucidate the effect of aminothiazoles on (a) osteoclastogenesis and the production of PGE 2 , IL-6, OPG and mPGES-1 in a co-culture model using PDL and RAW 264.7 cells stimulated by LPS and (b) osteoclastogenesis and bone resorption in peripheral blood mononuclear cells (PBMCs) stimulated with RANKL.
| MATERIALS AND METHODS

| PDL cells
Periodontal ligament cells were obtained from the root surface of extracted teeth without any clinical signs of periodontal disease from three healthy donors and isolated as previously described. 24 The study was approved by the Regional Ethical Review Board Stockholm and informed consent was obtained from the donors. previously determined by dose-response experiments. 23 The cells were incubated for 48 hours at 37°C in 100% humidity with 5% CO 2 and 800 μL of medium was collected and stored in −20°C for PGE 2 , OPG and IL-6 analysis. Thereafter, the cells were re-stimulated with 800 μL medium containing the same reagents as described above to further allow osteoclast differentiation of RAW 264.7 cells.
After 4 days in total, the experiment was stopped and the cell layers were fixed in 2% formaldehyde and stained for the osteoclast marker TRAP (Supporting Information).
| Differentiation of PBMCs
Peripheral blood mononuclear cells were purified from buffy coats donated by five healthy males who had given their informed consent and samples were collected from the plastic wells on day 6 and from the bone slices on days 9 and 12. To minimise proteolysis, cysteine protease inhibitor E64 (10 ng/mL; Sigma-Aldrich) was added to the medium samples, which were used for analyses of bone resorption.
The cells from the plastic wells and bone slices were stained for TRAP, as described in Supporting Information.
| Bone resorption
The TRAP-stained bone slices from day 12 were imaged in coverslipbottomed chambers, immersed in H 2 O, using 60x water immersion objective and NikonA1+ confocal laser microscope system (Nikon, Tokyo, Japan). We used reflection signal obtained with 405 nm laser to image bone contour and 647 nm laser to excite the TRAP stain.
To visualise the resorption pits, Z-stacks of bone contour and TRAP stain were captured and processed to volumetric 3D projections with ImageJ plugin collection Fiji (2.0.0-rc-65/1.52b) and to videos scrolling through the stacks (Videos S1-S4).
To quantify bone resorption, culture medium from the days 9 and 12 was analysed for C-terminal cross-linking telopeptides of type I collagen (CTX-I) using Crosslaps for Culture CTX-I ELISA kit (AC-07F1, Ids, Frankfurt am Main, Germany) according to the manufacturer's instructions.
| PGE 2 analysis
The levels of PGE 2 in the supernatants collected from the cell cultures were analysed using a commercial PGE 2 enzyme immunoassay (EIA) kit (Cayman Chemicals, Ann Arbor, MI, USA) according to the manufacturer's instructions.
| Analysis of OPG and IL-6
Levels of OPG and IL-6 were analysed in the culture supernatants according to the manufacturer's instructions. The minimum detection levels of the assay were 1.9 pg/mL for OPG and 1.4 pg/mL for IL-6.
| Quantitative RT-qPCR
Periodontal ligament cells were seeded in Petri dishes (500 000 cells/dish) and cultured as described above. After 24 hours of treatment with LPS in the absence or presence of TH-848 (0.2 μmol/L) and TH-644 (2 μmol/L), total RNA was isolated from the cells using the commercial RNeasy Mini Kit (Qiagen, Valencia, CA, USA). The amount of total RNA was quantified using a NanoVue Plus Spectrophotometer (GE Healthcare), and first-strand cDNA was obtained by reverse transcription of 1 μg of total RNA using the iScript 
| Statistical analysis
One-or two-way ANOVA with Tukey's or Sidak's corrections for multiple analyses were used to determinate statistical significance between treatment groups. Differences in treatment outcome were considered significant if P ≤ 0.05. To verify the origin of PDL cells, we analysed the expression of S100A4, which have previously been suggested as a specific marker for these cells. 27 All PDL cells used in this study were positive for S100A4 ( Figure S1 ). Figure 3A ).
| Aminothiazoles inhibit PGE
The levels of OPG, the RANKL decoy receptor, were also analysed in the same culture supernatants. The results showed that the production of OPG was not affected either by LPS or the aminothiazoles in the cultures ( Figure 3B ). 
|
| Aminothiazoles decrease osteoclastogenesis and bone resorption in PBMC cultures
In the next series of experiments, human CD14 + PBMCs were used to investigate the effect of aminothiazoles on osteoclast formation. Figure 5C and Videos S1 and S2).
Similar to the previous results, aminothiazole TH-644 (2 μmol/L) did not inhibit bone resorption pits formation ( Figure 5C and Video S3).
As our results did not show any effect of 2 μmol/L TH-644 on formation of osteoclasts or resorption pits, we tested higher concentration, 15 μmol/L, of this inhibitor, as this concentration was also used for RAW 264.7 cells. Similar to TH-848, TH-644 also inhibited formation of both osteoclasts ( Figure 5D ) and bone resorption pits ( Figure 5E ). 
| DISCUSSION
Periodontitis is a chronic inflammatory disease with a multifactorial pathogenesis where bacterial load, host immune response, systemic inflammatory diseases and environmental factors, collectively contributing to the destruction of tissue and alveolar bone. 28 In an attempt to investigate the effect of mPGES-1 inhibitors on osteoclast formation and bone resorption, we used a co-culture model of fibroblast-like PDL cells and osteoclast progenitor cells RAW 264.7
as well as PBMCs stimulated by LPS or RANKL. The results from the current study showed that LPS stimulate to PGE 2 , the production of the inflammatory cytokine IL-6 was increased by LPS, although the levels of IL-6 were not affected by aminothiazoles, highlighting the latter as specific PGE 2 inhibitors. When comparing the overall levels of IL-6, the greatest production was observed in cell-cell co- In the current study, we also investigated the effects of aminothiazoles on osteoclastogenesis and bone resorption using human PBMCs, stimulated with RANKL. Our results demonstrated that aminothiazoles (TH-848 and TH-644) inhibited the RANKL-induced osteoclast differentiation. In addition, both aminothiazoles were able to prevent resorption pits formation, when RANKL-treated PBMCs were cultured on the bone slices. Moreover, we performed the quantification of the inhibitory effect of aminothiazoles on the RANKL-induced bone loss by the CTX-I assay, revealing that both TH-848 and TH-644 reduced the levels of bone resorption marker.
The inhibition of bone resorption by aminothiazoles, at the concentrations used in the current study, was higher than 50%. These results are in line with our previous findings demonstrating that the aminothiazoles decreased alveolar bone destruction, by almost 50%, in experimental periodontitis in rat model. 22 In the current study, dif- that the aminothiazoles were identified based on their ability to bind to the active site of the human mPGES-1 enzyme, 22 and that RAW 264.7 cells are of murine origin. TH-644 may have a lower binding to the murine orthologue of mPGES-1 and higher concentrations were therefore required to obtain an inhibitory effect, as it has been reported that there are structural differences between human and rodent mPGES-1. 39, 40 However, the higher dose of TH-644 was also required for PBMCs cultures, as no effect could be observed by 2 μmol/L. In contrast to TH-644, TH-848 inhibitor was more potent, as it inhibited PGE 2 production and osteoclast formation at much lower concentrations in RAW 264.7 cells, as well as osteoclast formation and bone resorption in human PBMCs, indicating that the potency of this inhibitor seems to be independent of the origin of cells. This notion is also supported by our previous results demonstrating reduced alveolar bone loss in experimental-induced periodontitis in rats as well as inhibition of PGE 2 in human gingival fibroblasts, rat gingival fibroblasts and RAW 264.7 cells. 22, 23 The RAW 264.7 cells form osteoclast-like cells in response to both RANKL and LPS, 23, 32 which is inhibited by aminothiazoles. Furthermore, in human PBMCs, these aminothiazoles, targeting mPGES- NF-κB. In response to stimuli, the IKKα/IKKβ/NEMO (IKKs) complex is activated, leading to dissociation of IκBα/NF-κB complex, and subsequently to nuclear translocation of NF-κB. 44 PGE 2 -and RANKLmediated signalling converge at the Akt-, cAMP-Ca 2+ -calcineurinNFATc1- 45 and Wnt/β-catenin pathways, 42 and therefore both may be sensitive to aminothazoles. This suggestion is further supported by the findings that the expression of NFATc1, its binding and transcriptional activity of NFAT is reduced by antagonists of PGE 2 receptors 46 that are known to play important role in regulating bone formation and resorption. 45, 47 Furthermore, RANK-RANKL signalling pathway acting through NF-kB, MAPKs and AKT, induces the expression of different osteoclast-specific genes, including TRAP, MMP-9 and cathepsin K (CTSK), leading to osteoclast differentiation and bone resorption. 48, 49 It is noteworthy to mention that the levels of CTSK, the major protease in bone resorption, are reduced by aminothiazoles in LPS as well as RANKL-stimulated RAW 264.7 cells. 23 Periodontitis is a common chronic inflammatory disease resulting in the loss of alveolar bone supporting the teeth leading to tooth loss. Inhibitors of mPGES-1, including aminothiazoles, are relatively new compounds included to the group of substances with antiinflammatory properties. To our knowledge, up to date there are no mPGES-1 inhibitors approved for clinical use. Our group is the first to report and elucidate the impact of aminothiazoles as mPGES-1 inhibitors in a model of periodontitis in vitro. 22 The findings that aminothiazoles inhibit osteoclast differentiation and bone resorption in cell types tested, suggest these compounds as potential inhibitors of bone loss. 
